Abstract:Previously, we did a prospective study to compare pemetrexed plus carboplatin and gefitinib to either pemetrexed plus carboplatin or gefitinib alone as first-line therapy for lung adenocarcinoma patients harboring sensitive EGFR mutations (NCT02148380). The primary endpoint PFS was met at Oct 1, 2016. However, the OS of combinational group was not mature then [Han B, et al. Int J Cancer. 2017;141:1249-1256]. In the present study, we continued the OS follow-up until Sep 28 2018. The survival curves for OS were estimated with the Kaplan-Meier method and were compared between combination and gefitinib groups using the log-rank test. 2-years, 3-years survival rates were compared between combination and gefitinib groups using Pearson Chi-Square. Baseline characteristics of the intent-to-treat (ITT) population have been reported. At last day of follow-up (Sep 28 2018), 30 (75.0%) patients in the combinational group, 35 (85.4%) patients in the gefitinib group died. 2-year survival rates of combinational and gefitinib groups were 85.0% (34/40), 56.1% (23/41) (P=0.004), respectively. 3-year survival rates of combinational and gefitinib groups were 52.5% (21/40), 24.4% (10/41) (P=0.009), respectively. The median OS was 37.9 months (95%CI: 17.3-58.6) for the combinational group, which was substantially longer than the median OS for first-line gefitinib group (25.8 months [95%CI: 19.2-32.3]). The HR of combinational group versus gefitinib group was 0.56 (95%CI:0.34-0.91, P=0.02). 19del: The median OS was 51.0 months (95%CI: 36.6-65.5) for the combinational group, which was substantially longer than the median OS for first-line gefitinib group (29.8 months [95%CI: 26.7-32.9]). The HR of combinational group versus gefitinib group was 0.61 (95%CI:0.30-1.25, P=0.18). 21L858R: The median OS was 32.3 months (95%CI: 27.8-36.7) for the combinational group, which was substantially longer than the median OS for first-line gefitinib group (22.8 months [95%CI: 13.1-32.5]). The HR of combinational group versus gefitinib group was 0.50 (95%CI:0.25-1.00, P=0.05). Totally, 15 patients had baseline central nervous system (CNS) metastases. The median OS of patients who had baseline CNS metastases was 25.6 months (95%CI: 15.1-36.1); the median OS of patients who had no baseline CNS metastases was 31.7 months (95%CI: 28.2-35.2). The HR of CNS metastases group versus no CNS metastases group was 2.80 (95%CI:1.51-5.18, P=0.001). Among the combinational group, 20% (8/40) percent of patients had baseline CNS metastases. 17.1% (7/41) percent of patients in the gefitinib group had baseline CNS metastases. CNS: The median OS was 27.0 months, (95%CI: 21.8-32.3) for the combinational group, which was substantially longer than the median OS for first-line gefitinib group (15.5 months, 95%CI: 6.8-24.3). The HR of combinational group versus gefitinib group was 0.17 (95%CI:0.04-0.68, P=0.013). No CNS: The median OS was 47.4 months, 95%CI: 27.2-67.7 for the combinational group, which was substantially longer than the median OS for first-line gefitinib group (27.4 months, 95%CI: 23.0-33.7). The HR of combinational group versus gefitinib group was 0.57 (95%CI:0.32-0.99, P=0.044). The current study on lung adenocarcinoma patients harboring sensitive EGFR mutations showed that the combined treatment with pemetrexed plus carboplatin with gefitinib provide better survival benefits than gefitinib alone.

P1.03-052 Comparing EGFR-TKI with EGFR-TKI Plus Chemotherapy As 1st Line Treatment in Advanced NSCLC Patients with Both Mutated EGFR and Bim Polymorphism

EGFR-TKIs Plus Chemotherapy Demonstrated Superior Efficacy Than EGFR-TKIs Alone As First-Line Setting in Advanced NSCLC Patients with EGFR Mutation and BIM Deletion Polymorphism.

Gefitinib Plus Chemotherapy Versus Placebo Plus Chemotherapy in Egfr-Mutation- Positive Non-Small-Cell Lung Cancer after Progression on First-Line Gefitinib (impress): A Phase 3 Randomised Trial

Gefitinib or Erlotinib Vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

Epidermal Growth Factor Receptor‐tyrosine Kinase Inhibitor Therapy is Effective As First‐line Treatment of Advanced Non‐small‐cell Lung Cancer with Mutated EGFR: A Meta‐analysis from Six Phase III Randomized Controlled Trials

A Multi-Center Phase II Study of Toripalimab with Chemotherapy in Patients with EGFR Mutant Advanced NSCLC Patients Resistant to EGFR TKIs: Efficacy and Biomarker Analysis.

Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations.

Mefatinib As First-Line Treatment of EGFR Sensitizing Mutation-Positive Non-Small-cell Lung Cancer: A Phase III Efficacy and Biomarker Study.

Preliminary Results Of Randomized Phase Iii Study Comparing Efficacy And Safety Of First-Line Erlotinib Versus Carboplatin (Cbdca) Plus Gemcitabine (Gem) In Chinese Advanced Non-Small Cell Lung Cancer (Nsclc) Patients (Pts) With Egfr-Activating Mutations (Optimal)

1370Tip Befotertinib Versus Icotinib As First-Line Treatment in Patients with Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Controlled Phase III Study

1263P Tislelizumab + Chemotherapy Vs Chemotherapy Alone As First-Line Treatment for Locally Advanced/metastatic Nonsquamous NSCLC

Study of Gefitinib and Pemetrexed As First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation

The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials

Combination of EGFR-TKIs with Chemotherapy Versus Chemotherapy or EGFR-TKIs Alone in Advanced NSCLC Patients with EGFR Mutation

Pembrolizumab Plus Chemotherapy or Anlotinib Vs. Pembrolizumab Alone in Patients with Previously Treated EGFR-Mutant NSCLC.

Randomized controlled trial of chemotherapy plus geiftinib as ifrst-line treatment for patients with advancedEGFR mutation-positive lung adenocarcinoma

EGFR -TKI Combined with Pemetrexed Versus EGFR -TKI Monotherapy in Advanced EGFR -mutated NSCLC: A Prospective, Randomized, Exploratory Study

OA11.07 Chemotherapy Plus EGFR-TKI As First-Line Treatment Provides Better Survival for EGFR Mutation NSCLC Patients: Update Data for NCT02148380

The Efficacy Of Chemotherapy In The Advanced Nsclc Patients Who Failed With The Treatment Of Egfr-Tki

A Phase II Randomized Trial Evaluating Gefitinib Intercalated with Pemetrexed/platinum Chemotherapy or Pemetrexed/platinum Chemotherapy Alone in Unselected Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer

Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study